Target intelligence / Profile preview

Prolyl 4-hydroxylase subunit beta (P4HB)

Target
P4HB
Molecular classification
Enzyme, Protein disulfide isomerase family
01

Overview

Prolyl 4-hydroxylase subunit beta (P4HB) is the beta component of the prolyl 4-hydroxylase enzyme complex, which catalyzes the post-translational hydroxylation of proline residues in collagen precursors, a modification essential for the formation of stable collagen triple helices[2][4]. The beta subunit is identical to protein disulfide-isomerase, a multifunctional enzyme that assists in the formation, breakage, and rearrangement of disulfide bonds in the endoplasmic reticulum, and is essential for proper protein folding[2][4]. The enzyme functions as an α2β2 tetramer (two alpha and two beta subunits)[1]. It is widely expressed, tightly regulated, and plays key roles not only in collagen biosynthesis but also in maintaining redox homeostasis and protein quality control. Alterations of P4HB function or expression are implicated in several diseases, including fibrosis, cancer, and certain rare genetic syndromes such as HIDEA syndrome[1].

Other names
Protein disulfide-isomerasePDIA1PDIβ-subunit of prolyl 4-hydroxylase
02

Mechanism of action

Inhibition of P4HB disrupts disulfide bond formation and protein folding in the endoplasmic reticulum, potentially leading to accumulation of misfolded proteins and cellular stress[2]. Inhibit prolyl 4-hydroxylase activity, affecting collagen maturation and deposition[3].

03

Biological functions

Protein foldingCatalysis of disulfide bond formation, breakage, and isomerizationCollagen biosynthesis (as part of prolyl 4-hydroxylase complex)Hydroxylation of prolyl residues in preprocollagen
04

Disease associations

CancerNeurodegenerative disease (e.g., HIDEA syndrome)Other (e.g., fibrosis, due to roles in collagen production)
05

Safety considerations

Targeting P4HB can disrupt essential protein folding leading to broad effects on cell viability and toxicity[2].Interference with collagen biosynthesis may cause tissue fragility or fibrosis-related complications[3].
06

Interacting drugs

There are currently no well-established, clinically approved drugs that specifically target P4HB; experimental inhibitors and probes exist in research settings[2][4].
07

Biomarkers

P4HB expression level is being evaluated as a biomarker for cancer progression and poor prognosis in multiple tumor types[2].Mutation or altered expression may serve as a biomarker for specialized syndromes (e.g., HIDEA syndrome)[1].

Beyond the preview

Go deeper on Prolyl 4-hydroxylase subunit beta (P4HB).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Prolyl 4-hydroxylase subunit beta (P4HB).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call